.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cantor Fitzgerald
Chinese Patent Office
Boehringer Ingelheim
Federal Trade Commission
Baxter
McKesson
Cipla
Medtronic
Citi

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090186

« Back to Dashboard

NDA 090186 describes PEG 3350 AND ELECTROLYTES, which is a drug marketed by Mylan and Novel Labs Inc and is included in three NDAs. It is available from three suppliers. Additional details are available on the PEG 3350 AND ELECTROLYTES profile page.

The generic ingredient in PEG 3350 AND ELECTROLYTES is polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous. There are four hundred and seventeen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous profile page.

Summary for 090186

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 090186

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PEG 3350 AND ELECTROLYTES polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous FOR SOLUTION;ORAL 090186 ANDA Novel Laboratories, Inc. 40032-060 40032-060-19 278.26 g in 1 BOTTLE (40032-060-19)
PEG 3350 AND ELECTROLYTES polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous FOR SOLUTION;ORAL 090186 ANDA GAVIS Pharmaceuticals, LLC 43386-060 43386-060-19 278.26 g in 1 BOTTLE (43386-060-19)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SOLUTION;ORALStrength240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT
Approval Date:Jun 1, 2009TE:AARLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
QuintilesIMS
McKinsey
Cerilliant
McKesson
US Department of Justice
Accenture
Cantor Fitzgerald
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot